• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.影响经膀胱内卡介苗治疗的高级别非浸润性膀胱癌复发和进展的因素。
Pak J Med Sci. 2014 Mar;30(2):326-30. doi: 10.12669/pjms.302.4117.
2
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
3
Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.使用复发性肿瘤分级来指导卡介苗治疗:低级别复发并非良性。
Eur Urol Oncol. 2019 May;2(3):286-293. doi: 10.1016/j.euo.2018.08.013. Epub 2018 Sep 10.
4
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术(re-cTURBT)作为pT1期高级别(HG)疾病复发和进展的风险指标是否有用?一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
5
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2013 年更新版。
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
6
Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.根治性肾输尿管切除术治疗上尿路上皮癌后膀胱内卡介苗治疗后续非肌层浸润性膀胱癌的结果。
BJU Int. 2018 May;121(5):764-773. doi: 10.1111/bju.14111. Epub 2018 Jan 21.
7
Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.对于高级别非肌层浸润性膀胱癌,在膀胱内灌注卡介苗后进行抗炎治疗可能不会对肿瘤学结局产生负面影响。
World J Urol. 2017 Jan;35(1):105-111. doi: 10.1007/s00345-016-1853-z. Epub 2016 May 18.
8
Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理
Minerva Urol Nefrol. 2012 Dec;64(4):255-60.
9
Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).卡介苗(BCG)-RIVM 株膀胱内治疗的疗效和耐受性:高分级和复发性低分级非肌肉浸润性膀胱癌(NMIBC)的诱导和维持方案。
BMC Urol. 2014 Jan 27;14:11. doi: 10.1186/1471-2490-14-11.
10
Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.经尿道卡介苗免疫治疗用于治疗先前行前列腺放疗的高级别非肌肉浸润性膀胱癌。
Urol Oncol. 2013 Aug;31(6):857-61. doi: 10.1016/j.urolonc.2011.07.005. Epub 2011 Aug 24.

引用本文的文献

1
Development and validation of nomograms for predicting prognosis in patients with resectable bladder urothelial carcinoma undergoing radical cystectomy: a multicenter retrospective study.预测接受根治性膀胱切除术的可切除膀胱尿路上皮癌患者预后的列线图的开发与验证:一项多中心回顾性研究
Front Oncol. 2025 Jul 3;15:1571604. doi: 10.3389/fonc.2025.1571604. eCollection 2025.
2
Effect of smoking on the recurrence and progression of non-muscle-invasive bladder cancer.吸烟对非肌层浸润性膀胱癌复发和进展的影响。
Clin Transl Oncol. 2025 Apr;27(4):1695-1711. doi: 10.1007/s12094-024-03694-z. Epub 2024 Sep 12.
3
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.半乳糖凝集素-1和半乳糖凝集素-3表达在局限性膀胱尿路上皮癌中的预后价值
Transl Androl Urol. 2023 Feb 28;12(2):228-240. doi: 10.21037/tau-22-494. Epub 2023 Feb 7.
4
The impact of smoking on recurrence and progression of non-muscle invasive bladder cancer: a systematic review and meta-analysis.吸烟对非肌肉浸润性膀胱癌复发和进展的影响:系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2673-2691. doi: 10.1007/s00432-022-04464-6. Epub 2022 Nov 21.
5
Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor.吉西他滨联合乌苯美司膀胱灌注对膀胱肿瘤经尿道电切术后非肌层浸润性膀胱癌患者的临床疗效
Pak J Med Sci. 2022 May-Jun;38(5):1243-1249. doi: 10.12669/pjms.38.5.4599.
6
Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.雷帕霉素哺乳动物靶点(mTOR)复合物在膀胱癌进展和治疗中的新作用
Cancers (Basel). 2022 Mar 18;14(6):1555. doi: 10.3390/cancers14061555.
7
Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions.生活方式与非肌层浸润性膀胱癌的复发、进展及死亡率:现有研究与未来方向
Bladder Cancer. 2020;6(1):9-23. doi: 10.3233/blc-190249. Epub 2020 Mar 28.
8
Increased expression of POLR3G predicts poor prognosis in transitional cell carcinoma.POLR3G表达增加预示移行细胞癌预后不良。
PeerJ. 2020 Nov 3;8:e10281. doi: 10.7717/peerj.10281. eCollection 2020.
9
Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer.转移性膀胱癌患者化疗治疗中的社会人口学差异及其对生存的影响。
Urol Oncol. 2018 Jun;36(6):308.e19-308.e25. doi: 10.1016/j.urolonc.2018.03.008. Epub 2018 Apr 5.
10
Re: Factors affecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.关于:影响经膀胱内卡介苗治疗的高级别非侵袭性膀胱癌复发和进展的因素
Pak J Med Sci. 2014 Nov-Dec;30(6):1432. doi: 10.12669/pjms.306.6408.

本文引用的文献

1
Use of fluorescence in situ hybridization to predict response to bacillus Calmette-Guérin therapy for bladder cancer: results of a prospective trial.荧光原位杂交在预测膀胱癌卡介苗治疗反应中的应用:一项前瞻性试验的结果。
J Urol. 2012 Mar;187(3):862-7. doi: 10.1016/j.juro.2011.10.144. Epub 2012 Jan 15.
2
Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.女性性别和前列腺尿道原位癌是 T1G3 膀胱癌患者接受卡介苗治疗后复发、进展和疾病特异性死亡率的预后因素。
Eur Urol. 2012 Jul;62(1):118-25. doi: 10.1016/j.eururo.2011.10.029. Epub 2011 Oct 25.
3
Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?T1 高级别膀胱癌患者的预后因素和结果:我们能否识别需要早期行膀胱切除术的患者?
BJU Int. 2012 Apr;109(7):1026-30. doi: 10.1111/j.1464-410X.2011.10462.x. Epub 2011 Aug 24.
4
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.吸烟状况是非肌层浸润性膀胱癌经尿道切除术后复发的一个危险因素。
Eur Urol. 2011 Oct;60(4):713-20. doi: 10.1016/j.eururo.2011.07.010. Epub 2011 Jul 14.
5
Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder.肿瘤大小对膀胱Ta/T1期癌复发和进展的影响。
Scand J Urol Nephrol. 2011 Dec;45(6):388-92. doi: 10.3109/00365599.2011.590995. Epub 2011 Jun 16.
6
Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer.高级别非肌肉浸润性膀胱癌肿瘤位置的预后意义。
Med Oncol. 2012 Sep;29(3):1916-20. doi: 10.1007/s12032-011-9999-4. Epub 2011 Jun 9.
7
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.EAU 指南:非肌层浸润性膀胱尿路上皮癌,2011 年更新版。
Eur Urol. 2011 Jun;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.
8
Superficial bladder tumours: recurrence and progression.浅表性膀胱肿瘤:复发与进展
J Coll Physicians Surg Pak. 2011 Mar;21(3):157-60.
9
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.卡介苗优于表柔比星和干扰素-α2b 联合用于治疗 T1 期膀胱癌患者的膀胱内治疗。一项前瞻性、随机、北欧研究。
Eur Urol. 2010 Jan;57(1):25-31. doi: 10.1016/j.eururo.2009.09.038. Epub 2009 Oct 6.
10
Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.预测卡介苗治疗的非肌层浸润性膀胱癌患者的复发和进展:CUETO评分模型
J Urol. 2009 Nov;182(5):2195-203. doi: 10.1016/j.juro.2009.07.016. Epub 2009 Sep 16.

影响经膀胱内卡介苗治疗的高级别非浸润性膀胱癌复发和进展的因素。

Factors effecting recurrence and progression of high grade non invasive bladder cancer treated by intravesical BCG.

机构信息

Muhammad Kashif Khan, FCPS, Shaukat Khanum Memorial Cancer Hospital & Research Center Lahore, Lahore - Pakistan.

Irfan Ahmed, FRCS, Shaukat Khanum Memorial Cancer Hospital & Research Center Lahore, Lahore - Pakistan.

出版信息

Pak J Med Sci. 2014 Mar;30(2):326-30. doi: 10.12669/pjms.302.4117.

DOI:10.12669/pjms.302.4117
PMID:24772136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3999003/
Abstract

OBJECTIVE

The rate of recurrence in high grade non muscle invasive bladder cancer (NMIBC) is 70% with progression rate of 15-40% at 5 years. The treatment of high grade NMIBC is intravesical BCG therapy, however for high risk cases radical cystectomy is recommended. In this study we determined the response of high grade NMIBC to BCG therapy and the factors affecting it in south Asian population.

METHODS

This retrospective cohort study was conducted on 64 patients treated with intravesical BCG for high grade NMIBC from Dec 2008 to July 2012. Smoking, tumor size, location and multiplicity were taken as prognostic factors. Recurrence and progression were determined by cystoscopy and upper tract imaging according to European Association of Urology guidelines. The association of prognostic factors with recurrence and progression was determined.

RESULTS

The rate of recurrence and progression was found to 45.8% and 27.1% respectively after a mean follow up 28.36 months. Smokers had 4 times greater odds of progression of tumor as compared to non-smokers. Patients with large tumors had 6.7 times greater odds of progression as compared to patients with small tumors.

CONCLUSION

Smokers with large and multiple high grade NMIBC constitute the high risk group. These patients may be offered early radical cystectomy and advised to stop smoking.

摘要

目的

高级别非肌肉浸润性膀胱癌(NMIBC)的复发率为 70%,5 年内进展率为 15-40%。高级别 NMIBC 的治疗方法是膀胱内卡介苗(BCG)治疗,然而对于高危病例,建议进行根治性膀胱切除术。本研究旨在确定南亚人群中高级别 NMIBC 对 BCG 治疗的反应以及影响其反应的因素。

方法

这项回顾性队列研究纳入了 2008 年 12 月至 2012 年 7 月期间接受膀胱内 BCG 治疗的 64 例高级别 NMIBC 患者。吸烟、肿瘤大小、位置和数量被视为预后因素。根据欧洲泌尿外科学会指南,通过膀胱镜检查和上尿路成像来确定复发和进展情况。确定预后因素与复发和进展的相关性。

结果

平均随访 28.36 个月后,复发率和进展率分别为 45.8%和 27.1%。与非吸烟者相比,吸烟者肿瘤进展的可能性增加了 4 倍。与肿瘤较小的患者相比,肿瘤较大的患者进展的可能性增加了 6.7 倍。

结论

吸烟、肿瘤较大且数量较多的高级别 NMIBC 构成高危人群。这些患者可能会被建议早期接受根治性膀胱切除术并戒烟。